[1]
Boubertakh, B.; Silvestri, C. Di Marzo, V. Obesity: The fat tissue disease version of cancer. Cells, 2022, 11(12), 1872.
[2]
Ten-Blanco, M.; Flores, Á.; Pereda-Pérez, I.; Piscitelli, F.; Izquierdo-Luengo, C.; Cristino, L.; Romero, J.; Hillard, C.J.; Maldonado, R. Di Marzo, V.; Berrendero, F. Amygdalar CB2 cannabinoid receptor mediates fear extinction deficits promoted by orexin-A/hypocretin-1. Biomed. Pharmacother., 2022, 149, 112925.
[3]
Stark, T.; Iannotti, F.A.; Di Martino, S.; Di Bartolomeo, M.; Ruda-Kucerova, J.; Piscitelli, F.; Wotjak, C.T.; D’Addario, C.; Drago, F. Di Marzo, V.; Micale, V. Early blockade of CB1 receptors ameliorates schizophrenia-like alterations in the neurodevelopmental MAM model of schizophrenia. Biomolecules, 2022, 12(1), 108.
[4]
Keimpema, E. Di Marzo, V.; Harkany, T. Biological basis of cannabinoid medicines. Science, 2021, 374(6574), 1449-1450.
[5]
Abolghasemi, A.; Manca, C.; Iannotti, F.A.; Shen, M.; Leblanc, N.; Lacroix, S.; Martin, C.; Flamand, N. Di Marzo, V.; Silvestri, C. Assessment of the effects of dietary vitamin D levels on olanzapine-induced metabolic side effects: Focus on the endocannabinoidome-gut microbiome axis. Int. J. Mol. Sci., 2021, 22(22), 12361.
[6]
Forte, N.; Boccella, S.; Tunisi, L.; Fernández-Rilo, A.C.; Imperatore, R.; Iannotti, F.A.; De Risi, M.; Iannotta, M.; Piscitelli, F.; Capasso, R.; De Girolamo, P.; De Leonibus, E.; Maione, S. Di Marzo, V.; Cristino, L. Orexin-A and endocannabinoids are involved in obesity-associated alteration of hippocampal neurogenesis, plasticity, and episodic memory in mice. Nat. Commun., 2021, 12(1), 6137.
[7]
Ayoub, S.M.; Piscitelli, F.; Silvestri, C.; Limebeer, C.L.; Rock, E.M.; Smoum, R.; Farag, M.; de Almeida, H.; Sullivan, M.T.; Lacroix, S.; Boubertakh, B.; Nallabelli, N.; Lichtman, A.H.; Leri, F.; Mechoulam, R. Di Marzo, V.; Parker, L.A. Spontaneous and naloxone-precipitated withdrawal behaviors from chronic opiates are accompanied by changes in N-Oleoylglycine and N-Oleoylalanine levels in the brain and ameliorated by treatment with these mediators. Front. Pharmacol., 2021, 12, 706703.
[8]
Tunisi, L.; D’Angelo, L.; Fernández-Rilo, A.C.; Forte, N.; Piscitelli, F.; Imperatore, R.; de Girolamo, P. Di Marzo, V.; Cristino, L. Orexin-A/Hypocretin-1 controls the VTA-NAc mesolimbic pathway via endocannabinoid-mediated disinhibition of dopaminergic neurons in obese mice. Front. Synaptic Neurosci., 2021, 13, 622405.
[9]
Di Marzo, V. The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders. Dialogues Clin. Neurosci., 2020, 22(3), 259-269.
[10]
Rochefort, G.; Provencher, V.; Castonguay-Paradis, S.; Perron, J.; Lacroix, S.; Martin, C.; Flamand, N. Di Marzo, V.; Veilleux, A. Intuitive eating is associated with elevated levels of circulating omega-3-polyunsaturated fatty acid-derived endocannabinoidome mediators. Appetite, 2021, 156, 104973.
[11]
Manca, C.; Shen, M.; Boubertakh, B.; Martin, C.; Flamand, N.; Silvestri, C. Di Marzo, V. Alterations of brain endocannabinoidome signaling in germ-free mice. Biochim. Biophys. Acta Mol. Cell Biol. Lipids, 2020, 1865(12), 158786.
